SOMERSET, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, announced its participation at the Medical Practice Excellence: Financial and Operations Conference hosted by the Medical Group Management Association (MGMA). The event will take place from March 19-21 at the Hyatt Regency Grand Cypress in Orlando, Florida, and CareCloud will be exhibiting in booth 313.
MGMA, a renowned organization focused on the business of medical practice management since 1926, represents more than 350,000 physicians with a membership base of 15,000 group medical practices, from small private practices to large national health systems. MGMA provides innovative solutions and resources to help its members improve profitability, achieve financial sustainability, and set the industry benchmark for physician compensation and other key performance indicators.
The MGMA conference offers attendees the opportunity to gain valuable insights from both financial and operational perspectives and stay informed about the latest trends and topics that will shape the future success of medical practice organizations.
CareCloud will showcase its comprehensive suite of technology-enabled services and solutions at booth 313, including its powerful revenue cycle management (RCM) solution, Concierge. Concierge can help healthcare providers improve cash flow, reduce denials and rejections, enhance the patient experience, and increase revenue. By leveraging advanced technology and automation to streamline and optimize the healthcare revenue cycle, Concierge can significantly reduce errors and identify missed revenue opportunities, leading to improved financial sustainability for healthcare organizations.
"MGMA provides an invaluable platform for healthcare professionals to connect, learn, and advance in the ever-evolving healthcare industry,” said Brian Zelenka, CareCloud’s vice president of marketing. “For CareCloud, attending the MGMA financial and operations conference is not only an opportunity to showcase our innovative solutions, but also to understand the needs and challenges of medical practices, ultimately leading to better solutions and improved patient outcomes."
For more information about CareCloud's comprehensive suite of technology-enabled services and solutions, visit carecloud.com/solutions.
About CareCloud
CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to improve patient care, while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at www.carecloud.com.
Follow CareCloud on LinkedIn, Twitter and Facebook.
SOURCE CareCloud
Company Contact:
Bill Korn
Chief Financial Officer
CareCloud
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Asher Dewhurst
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.m
Media Inquiries:
Alexis Feinberg
ICR Westwicke
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.23 |
Daily Volume: | 0 |
Market Cap: | US$136.690M |
September 29, 2025 September 25, 2025 August 05, 2025 August 04, 2025 July 17, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load